Efficacy and safety of Botulinum toxin A for improving esthetics in facial complex: A systematic review

Gangigatti, Ritu; Bennani, Vincent; Aarts, John M.; Choi, Joanne Jung Eun; Brunton, Paul

doi:10.1590/0103-6440202104127

Cited by 8 publications

(7 citation statements)

References 42 publications

(192 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The digital dermoscopy evaluation performed in our study revealed an evident reduction in the caliber of the telangiectasias, an effect which persistent until the end of the study. This is a new finding which has not been reported in previous studies [ 6 , 11 ].…”

Section: Discussionsupporting

confidence: 64%

“…A total of 22 adverse events occurred in 16 (57%) of the patients, a rate higher than what has been reported in studies using only the standard technique [ 11 ]. These events were probably related to the sum of the effects caused by both techniques: the standard aesthetic treatment, ranging from 120U to 210U for each patient, plus the 62.5U used for microinjections.…”

Section: Discussionmentioning

confidence: 71%

“…Several studies suggested that injections of microdoses of BTX-A may be an effective procedure for the management of excess facial sebum, facial pores, papules and pustules, facial erythema, and rosacea [ 6 , 10 , 11 ]. The generalizability of the results of those studies, however, is limited due to the heterogeneity in the population being studied, the distinct treatment protocols being evaluated, the assessment methods utilized to measure the outcomes and the different brands of the BTX-A studied [ 6 ].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Subjective and Objective Measurements of the Facial Effects of Microdoses of Botulinum Toxin

Hexsel,

Valente-Bezerra,

Mosena

et al. 2023

Dermatol Pract Concept

View full text Add to dashboard Cite

Introduction: Studies have suggested that botulinum toxin A may improve skin quality, and application protocols using hyper-diluted doses of botulinum toxin (microdosing) have been studied as a way to achieve therapeutic goals without fully paralyzing the targeted muscles. Objectives: To evaluate the effects of a combined protocol utilizing both the standard dosing and the microdosing of AbobotulinumtoxinA for the improvement of skin quality, measured by objective and subjective measurements. Methods: Thirty patients were treated with botulinum toxin using both the standard technique and the microdosing technique. Objective (Sebumeter®, Mexameter® and digital dermoscopy pictures) and subjective (Global Aesthetic Improvement Scale and a clinical scale for evaluating the quality of facial skin) measurements of the effects in the treated areas were taken to assess the efficacy of the treatment. Results: Digital dermoscopy showed a marked reduction of erythema and telangiectasias. Erythema and telangiectasias improved both on objective and subjective measurements. Skin oleosity, static rhytids, papules and pustules and enlarged pores improved on subjective measurements. Patient satisfaction was high (93%) despite the high rate of adverse events (56%). Conclusions: The combined application of standard doses and microdoses of AbobotulinumtoxinA is effective in improving the overall quality of facial skin. The effects on erythema and telangiectasias suggest that it is an effective treatment option for patients with erythematotelangiectatic rosacea. When applying microdoses of botulinum toxin in the lower and mid-face, the doses and pattern of injection should be customized for each patient to reduce the occurrence of adverse events.

show abstract

Section: Discussionsupporting

confidence: 64%

Section: Discussionmentioning

confidence: 71%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Subjective and Objective Measurements of the Facial Effects of Microdoses of Botulinum Toxin

Hexsel,

Valente-Bezerra,

Mosena

et al. 2023

Dermatol Pract Concept

View full text Add to dashboard Cite

show abstract

“…The patients mean age was 44.8 which consist with other studies. [7][8][9] American Society for Aesthetic Plastic Surgery statistics reported that 77% of BTX-A procedures were administered to patients of age 35-64, in 2011. 10 BTX-A injections usually preferred between early thirties and fifties before the facial wrinkles become static.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Botulinum Toxin Applications in a Tertiary Cosmetic Department

ÖRENAY,

TEMEL,

KARAOSMANOĞLU

2024

Ankara Eğitim Ve Araştırma Hastanesi Tıp Dergisi

View full text Add to dashboard Cite

Aim: Botulinum toxin type A (BTX-A) treatment for facial rejuvenation has been started to used widely and become the most common aesthetic procedure. The aim in this study to evaluate the patients features and outcomes who had Onabotulinumtoxin A. Material and Method: The data of the BTX-A patient’s gender, age, occupation, history of cosmetic procedures, history of disease, doses of the first and control injections, complications and expectations from the therapy collected from the medical records. The patients were divided into two groups as under the age of 45 and age of 45 and older. These groups were compared with each other in terms of mentioned variables. Results: A total of 200 patients included in this study. The mean botulinum toxin dose was 33.7 units and the mean control dose was 4.5 units. Three (1.5%) of the patients developed a complication, all of them were eyelid ptosis. Most common expectation from the toxin injection was to look more young (69%) and vigorous (75.5%). There were no significant difference between the under the age of 45 and 45 and older group in terms of total BTX-A dose and control dose and complication rate (p=0.8, p=0.5, p=0.6). Expectation of looking less angry and less saggy were significantly higher in the 45 year and older group (p=0.02, p=0.02). Conclusion: It is important to evaluate the patient’s gender, age and expectations from the botulinum toxin injection to get the highest efficiency from BTX-A injection.

show abstract

“…We believe that it is necessary to carry out a formal meta-analysis to increase the validity of the evidence synthesis for the effectiveness of BoNT in OBPI [ 17 ]. Additionally, patient demographics such as age have been found to be correlated to BoNT effectiveness when applied for purposes other than OBPI [ 18 , 19 ], and whether similar relationships can be found in OBPI deserves exploration.…”

Section: Introductionmentioning

confidence: 99%

The Effectiveness and Safety of Botulinum Neurotoxin in Obstetric Brachial Plexus Injury: A Systematic Review and Meta-Analysis

Chen

Lin

et al. 2022

Healthcare

View full text Add to dashboard Cite

Obstetric brachial plexus injury, also known as neonatal brachial plexus injury, is not unusual in newborns. Given the lack of a comprehensive synthesis of the available data on the effectiveness of botulinum neurotoxin (BoNT) in treating children with obstetric brachial plexus injury, we conducted a systematic review and meta-analysis. We searched PubMed, Embase, Web of Science, and Cochrane databases from inception to 25 November 2022. Outcomes were function of the shoulder and elbow joints, muscle power of the deltoid, biceps brachii and triceps brachii, and the recurrence rate of subluxation or dislocation after reduction of the shoulder joint after BoNT application. Meta-regression was conducted to assess the moderator effect of age. We included 11 case series and 2 cohort studies. Passive range of motion of shoulder external rotation (standardized mean difference [SMD], 0.678; 95% confidence interval [95%CI], 0.423 to 0.934), Active Movement Scale for shoulder external rotation (SMD, 0.47; 95%CI, 0.131 to 0.808), and active range of motion of elbow extension (SMD, 2.445; 95%CI, 1.556 to 3.334) increased significantly after BoNT. However, the modified Gilbert scale for shoulder abduction (SMD, 1.239; 95% CI, −0.2 to 2.678), the Toronto score for active elbow flexion (SMD, 1.099; 95% CI, −0.053 to 2.252), muscle power of deltoid (SMD, 0.675; 95% CI, −0.599 to 1.949), biceps brachii (SMD, 0.225; 95% CI, −0.633 to 1.083), and triceps brachii (SMD, 1.354; 95% CI, −1.493 to 4.202) did not reach statistical significance. The moderator effect of age was not significant (p = 0.88). Meta-analysis was not done for recurrence rate of subluxation or dislocation due to insufficient data. In conclusion, our data support BoNT use in patients with obstetric brachial plexus injury. However, definite conclusions cannot be drawn due to small sample size and the lack of randomized controlled trials. More research is warranted to clarify the effectiveness of BoNT in patients with obstetric brachial plexus injury by using standardized injection protocols and outcome measurements.

show abstract

Efficacy and safety of Botulinum toxin A for improving esthetics in facial complex: A systematic review

Cited by 8 publications

References 42 publications

Subjective and Objective Measurements of the Facial Effects of Microdoses of Botulinum Toxin

Subjective and Objective Measurements of the Facial Effects of Microdoses of Botulinum Toxin

Evaluation of Botulinum Toxin Applications in a Tertiary Cosmetic Department

The Effectiveness and Safety of Botulinum Neurotoxin in Obstetric Brachial Plexus Injury: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About